Response to Yilmaz et al

Affiliations

¹ Medical Oncology Department, Instituto de Investigación Sanitaria San Carlos (IdISSC).
² Department of Otolaryngology-Head and Neck Surgery, Instituto de Investigación Sanitaria San Carlos (IdISSC).
³ Radiation Oncology Department, Hospital Clínico Universitario San Carlos, Madrid, Spain.
⁴ Medical Oncology Department, Aliada Cancer Center, Lima, Perú.
⁵ Medical Oncology Department, Clínica San Felipe, Lima, Perú.
⁶ Medical Oncology Department, Hospital María Auxiliadora, Lima, Perú.
⁷ Radiology Department, Hospital Clínico Universitario San Carlos, Madrid, Spain.
⁸ Nuclear Medicine Department, Hospital Clínico Universitario San Carlos, Hospital Clínico Universitario San Carlos, Madrid, Spain.
⁹ Pathology Department, Hospital Clínico Universitario San Carlos, Madrid, Spain.

Santiago Cabezas-Camarero et al. Anticancer Drugs. 2024.

. 2024 Jun 1;35(5):481-482.

doi: 10.1097/CAD.0000000000001585. Epub 2024 Apr 3.

¹ Medical Oncology Department, Instituto de Investigación Sanitaria San Carlos (IdISSC).
² Department of Otolaryngology-Head and Neck Surgery, Instituto de Investigación Sanitaria San Carlos (IdISSC).
³ Radiation Oncology Department, Hospital Clínico Universitario San Carlos, Madrid, Spain.
⁴ Medical Oncology Department, Aliada Cancer Center, Lima, Perú.
⁵ Medical Oncology Department, Clínica San Felipe, Lima, Perú.
⁶ Medical Oncology Department, Hospital María Auxiliadora, Lima, Perú.
⁷ Radiology Department, Hospital Clínico Universitario San Carlos, Madrid, Spain.
⁸ Nuclear Medicine Department, Hospital Clínico Universitario San Carlos, Hospital Clínico Universitario San Carlos, Madrid, Spain.
⁹ Pathology Department, Hospital Clínico Universitario San Carlos, Madrid, Spain.

No abstract available

References

1. Yilmaz MT, Sari SY, Yazici G. In regard to Cabezas-Camarero et al. Anticancer Drugs 2023; 34:1202–1204.
1. Sari SY, Yilmaz MT, Aktas BY, Aksoy S, Gullu I, Cengiz M, et al. Results of concurrent radiotherapy and immunotherapy in recurrent and metastatic head and neck cancer: a single-center experience. Oral Oncol 2022; 124:105658.
1. Yazici G, Gullu I, Cengiz M, Elmali A, Yilmaz MT, Aksoy S, et al. The synergistic effect of immune checkpoint blockade and radiotherapy in recurrent/metastatic sinonasal cancer. Cureus 2018; 10:e3519.
1. Tao Y, Biau J, Sun XS, Sire C, Martin L, Alfonsi M, et al. Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial. Ann Oncol 2023; 34:101–110.
1. Tao Y, Aupérin A, Sun X, Sire C, Martin L, Coutte A, et al. Avelumab–cetuximab–radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: the safety phase of a randomised phase III trial GORTEC 2017-01 (REACH). Eur J Cancer 2020; 141:21–29.